ArticlePituitary2015
IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.
Article in Pituitary, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Recurrent acromegaly: a systematic review on therapeutic approaches.BMC endocrine disorders · 2024Pooled it
- HOMA-IR in acromegaly: a systematic review and meta-analysis.Pituitary · 2021Pooled it
- Thyroid abnormalities in acromegaly in the era of improved disease control: a two-stage study.Journal of endocrinological investigation · 2026Article
- The relationships among nutrition, body composition, muscle strength and physical performance in patients with acromegaly.Archives of endocrinology and metabolism · 2026Observational
- Cumulative effects of lifelong systemic excess growth hormone on postcranial skeletal morphology in adult mice.Journal of anatomy · 2026Article
- Evaluation of temporal muscle thickness in subjects with acromegaly: a follow-up study.Therapeutic advances in endocrinology and metabolism · 2026Article
- Sarcopenic obesity and physical function in acromegaly: impact of disease control and evaluation using dual X-ray absorptiometry and multifrequency bioelectrical impedance analysis.Journal of endocrinological investigation · 2025Article
- Prospective, Longitudinal Study of Cancer Predictors and Rates in a New York City Cohort of 598 Patients With Acromegaly.The Journal of clinical endocrinology and metabolism · 2025Article
- Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly-A Preliminary Study.Biomedicines · 2025Article
- Assessment of sarcopenic obesity in patients with acromegaly.Pituitary · 2025Observational
- Acromegaly: diagnostic challenges and individualized treatment.Expert review of endocrinology & metabolism · 2025Review
- Temporal and masseter muscle evaluation by MRI provides information on muscle mass and quality in acromegaly patients.Pituitary · 2024Article
- Body Composition, Sarcopenia, and Serum Myokines in Acromegaly: A Narrative Review.Journal of bone metabolism · 2024Article
- Skeletal Muscle Evaluation in Patients With Acromegaly.Journal of the Endocrine Society · 2024Review
- Persistent Deficits in Bone Quality in Treated Acromegaly: Evidence From Assessments of Microstructure.Journal of the Endocrine Society · 2023Article
- Article
- Article
- Age, body composition parameters and glycaemic control contribute to trabecular bone score deterioration in acromegaly more than disease activity.Frontiers in endocrinology · 2023Article
- Changes in Cross-Sectional Area of the Median Nerve and Body Composition Parameters after Treatment of Acromegaly: 1 year Follow-Up.International journal of endocrinology · 2022Article
- Body Composition in Acromegaly According to Disease Activity - Performance of Dual X-Ray Absorptiometry and Multifrequency Bioelectrical Impedance Analysis.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
purposeActivity of acromegaly is gauged by levels of GH and IGF-1 and epidemiological studies demonstrate that their normalization reduces acromegaly's excess mortality rate. However, few data are available linking IGF-1 levels to features of the disease that may relate to cardiovascular (CV) risk. Therefore, we tested the hypothesis that serum IGF-1 levels relative to the upper normal limit relate to insulin sensitivity, serum CV risk markers and body composition in acromegaly.
methodsIn this prospective, cross-sectional study conducted at a pituitary tumor referral center we studied 138 adult acromegaly patients, newly diagnosed and previously treated surgically, with fasting and post-oral glucose levels of endocrine and CV risk markers and body composition assessed by DXA.
resultsActive acromegaly is associated with lower insulin sensitivity, body fat and CRP levels than acromegaly in remission. %ULN IGF-1 strongly predicts insulin sensitivity, better than GH and this persists after adjustment for body fat and lean tissue mass. %ULN IGF-1 also relates inversely to CRP levels and fat mass, positively to lean tissue and skeletal muscle estimated (SM(E)) by DXA, but not to blood pressure, lipids, BMI or waist circumference. Gender interacts with the IGF-1-lean tissue mass relationship.
conclusionsActive acromegaly presents a unique combination of features associated with CV risk, reduced insulin sensitivity yet lower body fat and lower levels of some serum CV risk markers, a pattern that is reversed in remission. %ULN IGF-1 levels strongly predict these features. Given the known increased CV risk of active acromegaly, these findings suggest that of these factors insulin resistance is most strongly related to disease activity and potentially to the increased CV risk of active acromegaly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.